clinical manifestations are variable, ranging from localized abscess formation to septicemia.
Melioidotic bone and joint infections are rarely reported but are an established entity. The knee joint is the most commonly affected joint in melioidosis, followed by the ankle, hip and shoulder joints. Melioidosis should be in the differential diagnosis of bone and joint infections in residents or returning travelers from the endemic area. Melioidosis diagnosis is missed in many parts of the world due to the lack of awareness of this infection and limited laboratory training and diagnostic techniques.
It also mimics other diseases such as tuberculosis. Delay in the diagnosis, or the initiation of appropriate and effective treatment against melioidosis, could worsen the outcome. Initial therapy with ceftazidime, or carbapenem with or without cotrimoxazole is recommended, followed by the oral eradication therapy (based on the antimicrobial susceptibility) with amoxicillin/clavulanic acid or cotrimoxazole. Surgical intervention remains important. This paper reviews current literature on the epidemiology, clinical features, diagnosis, and management of melioidotic bone and joint infections.
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INTRODUCTION
Burkholderia pseudomallei (B. pseudomallei) is a causative agent of a severe and fatal infectious disease which is called melioidosis. B.
pseudomallei, a Gram-negative bacterium, is a water and soil pathogen in Eastern Asia and Northern Australia. Melioidosis has emerged as an important cause of morbidity and mortality for the last several decades in the Southeast hemisphere. Melioidosis has expanded its occurrence from the tropics to other parts of the world such as other Asian regions, South America and the Caribbean [1] [2] [3] [4] [5] . B. pseudomallei can infect healthy individuals, but it is seen more commonly in patients with co-morbidities such as diabetes mellitus, malignancy and immunosuppression. Clinical manifestations of melioidosis range from latent infection, localized cutaneous lesions, sub-acute pneumonia, bone and joint infections, abscesses in body organs and cranial abscesses to life-threatening septicemia [1, 3, 6, 7] .
The clinical presentations of bone and joint infections due to B. pseudomallei are indistinguishable from other infectious causes.
Melioidosis should be considered in the differential diagnosis in patients from the disease endemic area, or who are returning from these areas. Early diagnosis can be made using the laboratory and clinical parameters to prompt administration of appropriate antimicrobial therapy, and achieve better prognostic outcome [5] . Mortality in acute severe melioidosis even with appropriate treatment still remains considerably high, ranging from 30% to 47% [8] . This article reviews the microbiology, epidemiology, clinical features, diagnosis, management and aspects of melioidosis particularly associated with bone and joint infections. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
MICROBIOLOGY
Burkholderia pseudomallei, previously known as Pseudomonas pseudomallei, is an aerobic, motile, non-spore forming, intracellular, soil saprophyte which can be found in wet soil and surface water [9, 10] . It is an oxidase-positive, Gram-negative bacillus with bipolar staining, (appears as a safety pin in the Gram stain film) which grows easily on commonly used media in the microbiology laboratory at 37°C. Variation in the colonial morphology can be noted; smooth colonies appear in young culture, while wrinkled and dry colonies appear in old culture [11, 12] . B. pseudomallei is able to resist hostile conditions such as extreme temperature, nutrient deficiency, acidic and alkaline conditions, dehydration and antiseptics and disinfectants [11, 12] reports from different regions of the world [5] . One study [22] from an endemic area in Northern Australia reported a 7.6% incidence of bone and joint infections in melioidosis patients, which was much less than a melioidosis case series of bone and joint infections from Thailand (14-27% incidence) [4, 23, 24] . A total of 29% patients with melioidosis in Brunei had bone and joint infections [5] . dehydrogenase deficiency, and systemic lupus erythematosus (SLE) [1] . Diabetes mellitus is the most important predisposing risk factor, and it increases the risk of melioidosis by 100-fold [19, 22, 23, 29] . The underlying comorbidities lead to immune dysfunction such as impaired polymorphonuclear phagocyte functions, so impaired phagocytic cells fail to clear this organism. It is thought that the immune deficiency increases the risk of melioidosis [30, 31] . One study reported that there is a 5.7 times higher risk of septic arthritis in melioidotic patients with diabetes mellitus, SLE and chronic renal failure [24] . Melioidosis in bone and joint infection is more common in males [4, 23] . This may be the case because males are exposed to B. pseudomallei while working in the rice paddies and they may be more involved in other outdoor activities. Prominent features in septic arthritis are swelling, tenderness, redness, and heat around joints [21, 24] . In melioidotic bone and joint infections, the presentation picture is usually chronic in nature, such as persistent fever rather than shock or respiratory failure, and overall mortality is low in this group [23] . Either single or multiple bone or joint involvement is observed in the past in musculoskeletal infections due to melioidosis. B.
MODES OF TRANSMISSION

CLINICAL FEATURES
pseudomallei mainly causes infections in knee and hip joints (Table 1) . It also affects the shoulder and other joints. Increased vascular supply in the metaphyseal regions of long bones helps it spread easily to bones and joints.
One recent study [32] Among joints, knee joints (41 patients) were the most affected joint; followed by ankle (20) , hip (15) , and shoulder (10) joints. Among bones, the femur and tibia were more involved than upper limb bones. This study also showed three patients suffering with discitis. The high incidence of knee joint involvement was recorded in these two studies [23, 32] . On the contrary, Kosuwon et al. [24] (1) collection of an appropriate sample; for example, needle aspiration from the abscess, such as a psoas abscess, or bone in the case of osteomyelitis, tissue or bone in discitis, tissue from ulcers or wounds, and blood cultures, (2) transportation of the samples in appropriate media, or in a sterile container, to the microbiology laboratory without any delay, (3) handling of the samples by trained and experienced laboratory staff, (4) processing using appropriate media, incubating and using the best methods to identify this organism, (5) use of specific antimicrobial discs which are used as intravenous or oral therapy for the treatment of melioidosis. Breach of any of the above-mentioned steps may lead to low chances of isolation of B. pseudomallei [1, 3, [35] [36] [37] .
Isolation of B. pseudomallei from the clinical specimens is considered to be the gold standard in the diagnosis of melioidosis. Isolation of B. pseudomallei from clinical samples is regarded as a significant isolate. Use of selective media for processing samples from non-sterile sites is helpful in suppressing commensal organisms, which otherwise can overgrow and give a false-negative result. A modified Ashdown media which contains colistin is currently used in the laboratories for the isolation of this organism [1, 36, 37] . Serology may be helpful in cases of culture-negative results, or in the absence of clinical samples from patients with melioidosis. However, the serology results should be interpreted cautiously in endemic areas, where local populations have raised melioidosis antibody levels. A group of researchers from north eastern Thailand reported that the indirect hemagglutination assay has a 95% sensitivity but the specificity is low (59%). In this study, patients with bacterial infections had a high titer of 1:1280 [38] . One Malaysian group developed an indirect immunofluorescence test using whole-cell antigen for the detection of total antibodies to B. pseudomallei. They found this test quite rapid and reliable [39] . A raised B. pseudomallei antibody titer in healthy individuals is probably due to repeated natural exposure to this saprophytic organism during outdoor activities. Molecular methods, for instance Polymerase Chain Reaction, or Pulsed Field Gel Electrophoresis, are being employed in the clinical and research laboratories; these are less sensitive than gold-standard culture results [40] .
TREATMENT
Normally systemic antimicrobial therapy active against B. pseudomallei, vigorous and repeated washouts, and several extensive debridements of infected bone are the cornerstones of treatment of bone and joint infections.
Prompt administration of antibiotics remains important to reduce morbidity and mortality.
Inflammatory markers and clinical signs of improvement are used to gauge the response to the specific therapy for melioidotic bone and joint infections. Intravenous antimicrobial therapy should be prolonged for deep-seated infection or complicated infections from four to eight weeks followed by the oral maintenance therapy for a minimum of 12 weeks (Tables 2, 3) [1, 4, 28, 31, 41] . Mortality was quite high before the antibiotic era. In an open-labeled randomized trial, the group compared the efficacy of ceftazidime (120 mg/kg/day) with ''conventional therapy'' (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day) in the treatment of severe melioidosis. Ceftazidime was associated with 50% (74-37%) reduction in mortality rate than the conventional therapy [42] . Ceftazidime has become the drug of choice for intensive therapy after this study.
Ceftazidime, or a member of the carbapenem group, is the drug of choice to treat this infection, followed by oral cotrimoxazole as a monotherapy or amoxicillin-clavulanic acid [41, 43, 44] . On the other hand, Inglis suggests the use of ceftazidime, meropenem or imipenem and trimethoprim-sulfamethoxazole and folic acid in the acute phase followed by any two antibiotics from the group of trimethoprim-sulfamethoxazole, doxycycline, and amoxicillin-clavulanic acid, as eradication therapy in deep-seated infections [11] . One study from Malaysia showed a low-level resistance to the commonly used antibiotics for the treatment of melioidosis. In this study, all isolates (170) of B. pseudomallei appeared [50] . Relapse should be considered and treated as a first episode [50] .
CONCLUSION
In endemic areas, B. pseudomallei should be considered as one of the causative agents of bone and joint infections because of its rising incidence and high rate of morbidity and mortality if not diagnosed and treated early on. A high index of suspicion of melioidosis is required to make the diagnosis. Isolation of B. pseudomallei from clinical specimens is considered to be the gold standard; however, to achieve this, samples must be processed carefully and in the appropriate media.
Treatment of melioidosis affecting bones and joints consists of antimicrobial therapy coupled with surgical management including washouts of joints and debridement of infected bone.
Those patients with deep-seated or complicated infections require intravenous antibiotics for 4-8 weeks, followed by oral antibiotics for a minimum of 12 weeks. Ceftazidime is usually the intravenous antibiotic of choice, which is followed by oral therapy such as cotrimoxazole.
Some countries are now using outpatient antimicrobial therapy for their clinically stable patients. Unfortunately no vaccine has yet been developed for this disease, which makes the awareness and understanding of melioidotic bone and joint infections, and the need for timely diagnosis and treatment, all the more relevant to microbiologists today. 
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